⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ERNA News
Ernexa Therapeutics Inc. Common Stock
Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing
globenewswire.com
ERNA
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
globenewswire.com
ERNA
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
globenewswire.com
ERNA
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
accessnewswire.com
AIM
AKTX
CNSP
DARE
NVNO
ERNA
GRI
MBRX
OTLK
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
globenewswire.com
ERNA
Three Biotechs Deliver Catalysts to Watch
globenewswire.com
NTHI
ERNA
VIVS
LLY
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
globenewswire.com
ERNA
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
globenewswire.com
ERNA
Form 8-K
sec.gov
ERNAW
ERNA
Form 8-K
sec.gov
ERNAW
ERNA